인간 표피성장인자 수용체 2(HER2) 양성 위암 시장 보고서(2026년)

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a form of gastric or gastroesophageal junction cancer in which tumor cells exhibit abnormally high expression of the HER2 protein or amplification of the HER2 gene, leading to enhanced cancer cell growth. This specific subtype can be addressed with targeted treatment options, resulting in improved therapeutic outcomes for suitable patients.

The primary treatment approaches for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer include chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy involves the use of potent drugs that circulate throughout the bloodstream to eliminate rapidly dividing cancer cells, including those associated with HER2-positive gastric cancer. These treatments are applied across multiple disease stages, including stage I, stage II, stage III, and stage IV, and are utilized by various end users such as ambulatory surgery centers, hospitals, specialty clinics, and others.

Tariffs have affected the HER2-positive gastric cancer market by increasing costs for imported targeted therapies, monoclonal antibodies, and advanced diagnostic equipment. Segments such as HER2-targeted therapies and antibody-drug conjugates are particularly impacted, with regions like North America and Europe facing moderate price adjustments due to import duties. While tariffs increase treatment costs and supply chain complexities, they also encourage local production, investment in domestic manufacturing, and the development of alternative therapeutic solutions.

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market research report is one of a series of new reports from The Business Research Company that provides human epidermal growth factor receptor 2 (her2)-positive gastric cancer market statistics, including human epidermal growth factor receptor 2 (her2)-positive gastric cancer industry global market size, regional shares, competitors with a human epidermal growth factor receptor 2 (her2)-positive gastric cancer market share, detailed human epidermal growth factor receptor 2 (her2)-positive gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer industry. This human epidermal growth factor receptor 2 (her2)-positive gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.31 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to limited availability of targeted therapies, reliance on conventional chemotherapy and radiation therapy, low awareness of her2-positive gastric cancer, restricted access to specialty clinics, slow adoption of immunotherapy.

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to development of novel antibody-drug conjugates, increasing clinical trials for her2-targeted therapies, rising healthcare infrastructure in emerging markets, growth in precision medicine and biomarker testing, expanding ambulatory surgery centers and specialty oncology clinics. Major trends in the forecast period include increasing adoption of her2-targeted therapies, rising awareness of gastric cancer subtypes, expansion of immunotherapy and monoclonal antibody usage, growth in personalized treatment approaches, enhanced focus on early detection and diagnostic testing.

The increasing use of targeted cancer therapy is anticipated to drive growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in the coming years. Targeted therapy, also referred to as personalized medicine, is a treatment strategy that employs specific drugs or agents to inhibit cancer growth by focusing on particular molecules involved in tumor development. The growth in the adoption of targeted therapies is largely attributed to advances in genetic profiling, which enable more precise treatments tailored to an individual's unique tumor characteristics, resulting in enhanced effectiveness and reduced side effects. In HER2-positive gastric cancer, targeted therapy works by directly targeting the HER2 protein, which is overexpressed in these tumors, thereby slowing disease progression and improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based professional membership organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023, including 7 for cancer and 3 for other diseases and conditions, up from 6 approvals in 2022. This trend highlights that the increasing adoption of targeted cancer therapy is fueling the growth of the HER2-positive gastric cancer market.

Key players in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are focusing on obtaining approvals for innovative therapies, such as advanced immunotherapy-enhanced combination regimens, which combine immune checkpoint inhibitors with targeted therapy and chemotherapy to substantially improve patient outcomes in first-line treatment settings. These regimens harness the immune system by blocking programmed death (PD)-1 or programmed death ligand (PD-L1) interactions while simultaneously targeting HER2 receptors and employing chemotherapeutic agents, thereby boosting anti-tumor activity and improving survival rates. For instance, in March 2025, Merck & Co., Inc., a U.S.-based biopharmaceutical company, received FDA approval for pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy as a first-line treatment for adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1. This combination therapy demonstrated significant improvements in median progression-free survival and overall survival compared to standard treatments. With an overall response rate of 73% and a longer median duration of response, this therapy represents a major advancement in the management of advanced HER2-positive gastric cancers.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. for an undisclosed sum. Through this acquisition, Pfizer aims to expand its oncology portfolio and strengthen its capabilities in targeted cancer therapies. Seagen Inc., a U.S.-based biotechnology company, specializes in treatments for HER2-positive gastric cancer.

Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market consists of sales of trastuzumab, pertuzumab, margetuximab, and lapatinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses human epidermal growth factor receptor 2 (her2)-positive gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human epidermal growth factor receptor 2 (her2)-positive gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Targeted Therapy
• 2) By Stage: Stage I; Stage II; Stage III; Stage IV
• 3) By End-User: Ambulatory Surgery Centers; Hospitals And Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Fluoropyrimidines; Platinum-Based Agents; Taxanes; Irinotecan; Anthracyclines
• 2) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Cancer Vaccines; Cytokine-Based Therapies
• 3) By Radiation Therapy: External Beam Radiation Therapy; Intensity-Modulated Radiation Therapy; Stereotactic Body Radiation Therapy; 3D Conformal Radiation Therapy
• 4) By Targeted Therapy: HER2-Targeted Therapies; Tyrosine Kinase Inhibitors; Antibody-Drug Conjugates; mTOR Inhibitors; PI3K/AKT/mTOR Pathway Inhibitors
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co Inc.; Bayer Aktiengesellschaft; Eli Lilly and Company; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Amgen Inc.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Genentech Inc.; Ono Pharmaceutical Co Ltd.; Shanghai Henlius Biotech Inc.; MacroGenics Inc.; Hutchison Medipharma Limited ; ALX Oncology Holdings Inc.; Taiho Pharmaceutical Co Ltd.; Ambrx Biopharma Inc.; LintonPharm Co Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Her2-Targeted Therapies
  • 4.2.2 Rising Awareness Of Gastric Cancer Subtypes
  • 4.2.3 Expansion Of Immunotherapy And Monoclonal Antibody Usage
  • 4.2.4 Growth In Personalized Treatment Approaches
  • 4.2.5 Enhanced Focus On Early Detection And Diagnostic Testing

5. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Analysis Of End Use Industries

• 5.1 Ambulatory Surgery Centers
• 5.2 Hospitals And Specialty Clinics
• 5.3 Oncology Research Centers
• 5.4 Pharmaceutical And Biotechnology Companies
• 5.5 Diagnostic Laboratories

6. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation

• 9.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
• 9.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Stage I, Stage II, Stage III, Stage IV
• 9.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
• 9.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
• 9.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
• 9.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
• 9.7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

10. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regional And Country Analysis

• 10.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 11.1. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 12.1. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 13.1. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 14.1. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 15.1. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 16.1. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 17.1. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 18.1. Taiwan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 19.1. South East Asia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 20.1. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 21.1. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 22.1. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 23.1. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 24.1. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 25.1. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 26.1. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 27.1. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 28.1. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 29.1. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 30.1. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 31.1. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 32.1. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 33.1. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

• 34.1. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Segmentation By Stage, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regulatory and Investment Landscape

36. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Company Profiles

• 36.1. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

37. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Other Major And Innovative Companies

• Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited, ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

38. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

40. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market High Potential Countries, Segments and Strategies

• 40.1 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer